A study of endocrine and metabolic variables in postmenopausal women with endometrial carcinoma.
Although an underlying endocrine-metabolic disorder has been implicated as causally related to the development of endometrial carcinoma, data to support such an association are ambiguous and/or contradictory. In this prospective study of 16 consecutive nonobese postmenopausal women with endometrial carcinoma and 16 cancer-free postmenopausal women matched for age and weight, fasting values for growth hormone (GH), insulin, prolactin, follicle-stimulating hormone, luteinizing hormone, estrone (E1), and estradiol (E2) were measured on 3 consecutive days. Intravenous glucose tolerance, pituitary GH release in response to arginine infusion, hyperglycemia, and hypoglycemia, and insulin secretion in response to arginine infusion and to hyperglycemia were analyzed. Our data show that these endocrine-metabolic profiles were not significantly different between the cancer patients and control subjects, suggesting that the postmenopausal women with endometrial cancer who is not obese exhibits no accountable endocrine or metabolic disorders.
D000230:Adenocarcinoma / Q000097:blood*; D000368:Aged; D001120:Arginine / Q000494:pharmacology; D004967:Estrogens / Q000097:blood; D005260:Female; D005947:Glucose / Q000494:pharmacology; D006065:Gonadotropins, Pituitary / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D007328:Insulin / Q000494:pharmacology; D008593:Menopause; D008875:Middle Aged; D011446:Prospective Studies; D011960:Receptors, Estrogen / Q000032:analysis; D014594:Uterine Neoplasms / Q000097:blood*
D004967:Estrogens; D006065:Gonadotropins, Pituitary; D007328:Insulin; D011960:Receptors, Estrogen; D013006:Growth Hormone; D001120:Arginine; D005947:Glucose